https://doi.org/10.4081/reumatismo.2019.1153
Infliximab in the treatment of Budd-Chiari syndrome in Behçet’s disease
Accepted: 17 July 2019
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Behçet’s disease is a chronic autoinflammatory disorder that usually presents with recurrent oral and genital ulcers, uveitis, skin lesions and arthritis. Any organ, however, can be involved and in a subgroup of patients the large vascular lesions are the predominant feature (vasculo-Behçet disease). We report a case of a 27-yearold man with Behçet’s disease who developed Budd-Chiari syndrome while on immunosuppressive therapy. Infliximab resulted in a rapid and total clinical remission. Literature data have shown that antitumor necrosis factor alpha (anti-TNF-α) agents including infliximab can suppress disease activity but there is no long-term experience on tapering and/or discontinuation of treatment under clinical remission. Our case supports the use of infliximab in vasculo-Behçet patients.
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- C. Cervini, G. Leardini, A. Mathieu, L. Punzi, R. Scarpa, Psoriatic arthritis: epidemiological and clinical aspects in a cohort of 1.306 italian patients , Reumatismo: Vol. 57 No. 4 (2005)
- I. Miniati, R. Saccardi, F. Pagliai, S. Guiducci, A. Bosi, S. Guidi, S. Urbani, A. Tyndall, M. Matucci Cerinic, The treatment of diffuse cutaneous systemic sclerosis with autologous hemopoietic stem cells transplantation (HSCT): our experience on 2 cases , Reumatismo: Vol. 57 No. 4 (2005)
- R. Scrivo, A. Spadaro, V. Riccieri, M. Bombardieri, M. Di Franco, D. Celestino, G. Valesini, Soluble P-selectin levels in synovial fluid and serum from patients with psoriatic arthritis , Reumatismo: Vol. 57 No. 4 (2005)
- D. Malesci, G. La Montagna, G. Valentini, The arthropathy of systemic sclerosis , Reumatismo: Vol. 57 No. 4 (2005)
- G. Brambilla, A. Brucato, Y. Adler, M. Bosetti, P. Coppini, A. Caforio, D. Spodick, B. Canesi, Recurrent acute idiopathic pericarditis: rheumatologic therapy, autoantibodies and long term outcome , Reumatismo: Vol. 59 No. 1 (2007)
- C. Botsios, P. Sfriso, A. Furlan, P. Ostuni, M. Biscaro, U. Fiocco, S. Todesco, L. Punzi, Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis , Reumatismo: Vol. 59 No. 1 (2007)
- P. Ostuni, M.E.C. Battista, A. Furlan, Efficacy of Carbopol 974P (Siccafluid) in the treatment of severe to moderate keratoconjunctivitis sicca (KCS) in patients with primary Sjögren’s syndrome (SS) not responding to standard treatment with artificial tears , Reumatismo: Vol. 57 No. 2 (2005)
- G. Armocida, M. Broggini, Gout in Valchiavenna in the XVII century: a case report , Reumatismo: Vol. 59 No. 1 (2007)
- A. Gava, A. Furlan, F. Navaglia, M. Miorin, M. Razetti, D. Basso, M. Plebani, L. Punzi, Utility of denaturing high performance liquid chromatography (DHPLC) for the diagnosis of mevalonate kinase deficiency in periodic fevers of autoinflammatory nature suspicion , Reumatismo: Vol. 61 No. 3 (2009)
- H. Marotta, R. Montisci, F. Tiso, S. Pontarollo, M. Rizzo, F. Tona, S. Iliceto, F. Cozzi, Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases , Reumatismo: Vol. 59 No. 4 (2007)
<< < 44 45 46 47 48 49 50 51 52 53 > >>
You may also start an advanced similarity search for this article.
